ArticleInvestigational new drugs2022

Synergistic cytotoxicity of the CDK4 inhibitor Fascaplysin in combination with EGFR inhibitor Afatinib against Non-small Cell Lung Cancer.

Adelina Plangger et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.